NO20064884L - Kjemisk fremgangsmate og ny krystallinsk form - Google Patents

Kjemisk fremgangsmate og ny krystallinsk form

Info

Publication number
NO20064884L
NO20064884L NO20064884A NO20064884A NO20064884L NO 20064884 L NO20064884 L NO 20064884L NO 20064884 A NO20064884 A NO 20064884A NO 20064884 A NO20064884 A NO 20064884A NO 20064884 L NO20064884 L NO 20064884L
Authority
NO
Norway
Prior art keywords
crystalline form
chemical process
new crystalline
crystalline
relates
Prior art date
Application number
NO20064884A
Other languages
English (en)
Norwegian (no)
Inventor
Darren Michael Caine
Ian Leonard Paternoster
Peter David Penberthy Shapland
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20064884(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0407521A external-priority patent/GB0407521D0/en
Priority claimed from GB0411688A external-priority patent/GB0411688D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20064884L publication Critical patent/NO20064884L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
NO20064884A 2004-04-02 2006-10-26 Kjemisk fremgangsmate og ny krystallinsk form NO20064884L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0407521A GB0407521D0 (en) 2004-04-02 2004-04-02 Chemical process
GB0411688A GB0411688D0 (en) 2004-05-25 2004-05-25 Chemical process
US57446704P 2004-05-26 2004-05-26
PCT/GB2005/001241 WO2005095328A1 (en) 2004-04-02 2005-03-30 Chemical process and new crystalline form

Publications (1)

Publication Number Publication Date
NO20064884L true NO20064884L (no) 2006-10-26

Family

ID=34963396

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064884A NO20064884L (no) 2004-04-02 2006-10-26 Kjemisk fremgangsmate og ny krystallinsk form

Country Status (13)

Country Link
US (1) US7846973B2 (de)
EP (1) EP1730104A1 (de)
JP (1) JP2007530652A (de)
AR (1) AR052301A1 (de)
AU (1) AU2005227733A1 (de)
BR (1) BRPI0509382A (de)
CA (1) CA2561400A1 (de)
IL (1) IL178064A0 (de)
MA (1) MA28558B1 (de)
NO (1) NO20064884L (de)
PE (1) PE20060678A1 (de)
TW (1) TW200536814A (de)
WO (1) WO2005095328A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066907A1 (en) * 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
IT1399912B1 (it) * 2010-04-29 2013-05-09 Lundbeck Pharmaceuticals Italy S Pa Processo di preparazione di ritodrina cloridrato.
JP5645762B2 (ja) * 2010-06-29 2014-12-24 日本ポリプロ株式会社 ポリオレフィンの結晶性分布分析方法およびその装置
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
GB201212081D0 (en) * 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
EP0069715B1 (de) 1981-07-08 1986-11-05 Aktiebolaget Draco Pulverinhalator
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AU570013B2 (en) 1982-10-08 1988-03-03 Glaxo Group Limited Medicament inhaler
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
CA1272917A (en) 1985-07-30 1990-08-21 Paul Kenneth Rand Devices for administering medicaments to patients
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
AU677776B2 (en) 1992-04-02 1997-05-08 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5495054A (en) 1994-05-31 1996-02-27 Sepracor, Inc. Tetrahydroindeno[1,2-D][1,3,2]oxazaboroles and their use as enantioselective catalysts
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
OA11558A (en) * 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
WO2004024728A2 (en) 2002-09-16 2004-03-25 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
TW200510277A (en) 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist

Also Published As

Publication number Publication date
AR052301A1 (es) 2007-03-14
US20100063157A1 (en) 2010-03-11
TW200536814A (en) 2005-11-16
JP2007530652A (ja) 2007-11-01
BRPI0509382A (pt) 2007-09-18
MA28558B1 (fr) 2007-04-03
US7846973B2 (en) 2010-12-07
AU2005227733A1 (en) 2005-10-13
KR20070000508A (ko) 2007-01-02
PE20060678A1 (es) 2006-08-02
WO2005095328A1 (en) 2005-10-13
IL178064A0 (en) 2006-12-31
CA2561400A1 (en) 2005-10-13
EP1730104A1 (de) 2006-12-13

Similar Documents

Publication Publication Date Title
NO20064884L (no) Kjemisk fremgangsmate og ny krystallinsk form
NO330968B1 (no) Ny fremgangsmate for syntesen av (1S)-4,5-dimetoksy-1-(metylaminometyl)-benzocyklobutan og addisjonssalter derav, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
NZ592533A (en) METHOD FOR THE PREPARATION OF N-(5-CHLORO-2-PYRIDINYL)-2-[[4-[(DIMETHYLAMINO) IMINOMETHYL] BENZOYL] AMINO]-5-METHOXY-BENZAMIDE, A FACTOR Xa INHIBITOR
RU2012103850A (ru) Би-арил-мета-пиримидиновые ингибиторы киназ
TW200637822A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
TW200510277A (en) Crystalline form of β2-adrenergic receptor agonist
TW200633981A (en) Process for the preparation of a 2-ethylaminopyridine derivative
MA32977B1 (fr) Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo(c(1,2)oxaborol-1-ol
CL2007002949A1 (es) Forma cristalina del compuesto 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil)-4-fluoro-n-((metil(1-metiletil)amino)sulfonil)benzamida; proceso para la preparacion de dicha forma cristalina; composicion fitoprotectora;
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
EP1829868A4 (de) Verfahren zur herstellung von (4,5-dihydroxyisoxazol-3-yl)thiocarboxamidinsalzen
NO20065321L (no) Fremgangsmate for fremstilling av clopidogrelhydrogensulfat polymorf for I
EA200870038A1 (ru) Способ получения аминов
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
MXPA05013751A (es) Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales.
TW200612959A (en) Method for preparing hydroxamic acids
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
IL185545A0 (en) Method of preparation of pure 4-pyrrolidinophenylbenzyl ether derivatives as maob inhibitors
NO20050885L (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
NO20082005L (no) Syntese av renininhibitorer omfattende en cyklotilfoyelsesreaksjon
EA200800200A1 (ru) Способ получения кристаллического периндоприла
MXPA04005305A (es) Nuevo polimorfo cristalino de clorhidrato de venlafaxina y metodos para preparacion del mismo.
WO2008101975A3 (en) New n-(3-phenylpropyl)benzamide derivatives
EA200901088A1 (ru) Способ получения 5-бензилокси-2-(4-бензилоксифенил)-3-метил-1н-индола

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application